Logo do repositório
 
Publicação

Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer

2022-09Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorNosrati, Hamed
dc.contributor.authorGhaffarlou, Mohammadreza
dc.contributor.authorSalehiabar, Marziyeh
dc.contributor.authorMousazadeh, Navid
dc.contributor.authorAbhari, Fatemeh
dc.contributor.authorBarsbay, Murat
dc.contributor.authorErtas, Yavuz Nuri
dc.contributor.authorRashidzadeh, Hamid
dc.contributor.authorMohammadi, Ali
dc.contributor.authorNasehi, Leila
dc.contributor.authorRezaeejam, Hamed
dc.contributor.authorDavaran, Soodabeh
dc.contributor.authorRamazani, Ali
dc.contributor.authorConde, João
dc.contributor.authorConde, João
dc.contributor.authorDanafar, Hossein
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentre for Toxicogenomics and Human Health (ToxOmics)
dc.contributor.pblElsevier
dc.date.accessioned2023-06-20T22:20:03Z
dc.date.available2023-06-20T22:20:03Z
dc.date.issued2022-09
dc.descriptionFunding Information: This work supported by the “ Iran National Science Foundation : INSF-98024375 ”, Iran's National Elites Foundation , and the “ University of Zanjan ”. We gratefully acknowledge the Zanjan University of Medical Science support. JC acknowledges financial support from the European Research Council - ERC Starting Grant 848325 . Y.N. Ertas acknowledges funding support from the 2232 International Fellowship for Outstanding Researchers Program of TÜBİTAK (Project No: 118C346 ). MB acknowledges the financial support of the International Atomic Energy Agency (IAEA) under coordinated research project F22070 (IAEA Research Contract No: 23192 ). Funding Information: This work supported by the “Iran National Science Foundation: INSF-98024375”, Iran's National Elites Foundation, and the “University of Zanjan”. We gratefully acknowledge the Zanjan University of Medical Science support. JC acknowledges financial support from the European Research Council - ERC Starting Grant 848325. Y.N. Ertas acknowledges funding support from the 2232 International Fellowship for Outstanding Researchers Program of TÜBİTAK (Project No: 118C346). MB acknowledges the financial support of the International Atomic Energy Agency (IAEA) under coordinated research project F22070 (IAEA Research Contract No: 23192). Publisher Copyright: © 2022
dc.description.abstractJanus heterostructures based on bimetallic nanoparticles have emerged as effective radiosensitizers owing to their radiosensitization capabilities in cancer cells. In this context, this study aims at developing a novel bimetallic nanoradiosensitizer, Bi2S3-Fe3O4, to enhance tumor accumulation and promote radiation-induced DNA damage while reducing adverse effects. Due to the presence of both iron oxide and bismuth sulfide metallic nanoparticles in these newly developed nanoparticle, strong radiosensitizing capacity is anticipated through the generation of reactive oxygen species (ROS) to induce DNA damage under X-Ray irradiation. To improve blood circulation time, biocompatibility, colloidal stability, and tuning surface functionalization, the surface of Bi2S3-Fe3O4 bimetallic nanoparticles was coated with bovine serum albumin (BSA). Moreover, to achieve higher cellular uptake and efficient tumor site specificity, folic acid (FA) as a targeting moiety was conjugated onto the bimetallic nanoparticles, termed Bi2S3@BSA-Fe3O4-FA. Biocompatibility, safety, radiation-induced DNA damage by ROS activation and generation, and radiosensitizing ability were confirmed via in vitro and in vivo assays. The administration of Bi2S3@BSA-Fe3O4-FA in 4T1 breast cancer murine model upon X-ray radiation revealed highly effective tumor eradication without causing any mortality or severe toxicity in healthy tissues. These findings offer compelling evidence for the potential capability of Bi2S3@BSA-Fe3O4-FA as an ideal nanoparticle for radiation-induced cancer therapy and open interesting avenues of future research in this area.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent3523963
dc.identifier.doi10.1016/j.bioadv.2022.213090
dc.identifier.issn2772-9508
dc.identifier.otherPURE: 46373680
dc.identifier.otherPURE UUID: 4e729b2a-5d5b-498e-8d80-364940dd61aa
dc.identifier.otherScopus: 85136533215
dc.identifier.otherPubMed: 36027669
dc.identifier.otherWOS: 000861397600004
dc.identifier.urihttp://hdl.handle.net/10362/154203
dc.identifier.urlhttps://www.scopus.com/pages/publications/85136533215
dc.language.isoeng
dc.peerreviewedyes
dc.subjectBismuth sulfide
dc.subjectIron oxide
dc.subjectJanus nanoparticles
dc.subjectRadiosensitizer
dc.subjectROS generation
dc.subjectX-ray irradiation
dc.subjectBiomedical Engineering
dc.subjectBiomaterials
dc.subjectBioengineering
dc.subjectSDG 3 - Good Health and Well-being
dc.titleMagnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast canceren
dc.typejournal article
degois.publication.titleBiomaterials advances
degois.publication.volume140
dspace.entity.typePublication
person.familyNameConde
person.givenNameJoão
person.identifier807432
person.identifier.ciencia-idA71C-B10E-255E
person.identifier.orcid0000-0001-8422-6792
person.identifier.ridF-2231-2011
person.identifier.scopus-author-id56992468300
rcaap.rightsopenAccess
relation.isAuthorOfPublication33ca4178-1b25-4b5e-ae16-b2500abe4c58
relation.isAuthorOfPublication.latestForDiscovery33ca4178-1b25-4b5e-ae16-b2500abe4c58

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1_s2.0_S2772950822003673_main_1_.pdf
Tamanho:
3.36 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: ToxOmics - Artigos em revista internacional com arbitragem científica